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Purpose: To examine the clinical efficacy and anti–inflammatory effects of tacrolimus eye drops; we studied the changes
in clinical ocular findings and measured tear eosinophil cationic protein (ECP) levels of atopic keratoconjunctivitis (AKC)
patients before and after the treatment.
Methods: Nine eyes of 9 patients (8 males, 1 female; mean age: 16.9±11.4 years; range: 6–44 years) diagnosed with
moderate or severe AKC disease were enrolled in this prospective study and treated with tacrolimus. All patients received
0.1% tacrolimus eye drops 2 times a day for 1 month. Tear samples were taken before and after treatment and ECP
concentrations were obtained. Corneal fluorescein staining and conjunctival injection, edema, and papillary formation
were graded on the recruitment day and one month later. Analysis of pre- and post-treatment findings was done using the
Wilcoxon signed test. The ECP concentrations were correlated with the clinical signs using Spearman correlation tests.
Results: Post-treatment tear ECP levels were significantly reduced compared to the pre-treatment level. Clinical corneal
scores also improved significantly after one month treatment with tacrolimus eye-drops. The mean conjunctival injection
and conjunctival edema scores were significantly (p<0.05) decreased after the drug therapy. Strong positive linear
correlations between ECP values and clinical signs were observed. Patients did not present side effects during the treatment
with tacrolimus.
Conclusions: In this pilot study, tacrolimus eye drops were found to reduce signs of AKC. ECP proved to correlate well
with clinical signs of AKC.
Atopic keratoconjunctivitis (AKC) is a chronic atopic
disease of the conjunctiva and cornea. The disease occurs in
both  children  and  adults  and  is  associated  with  atopic
dermatitis (AD). The male to female ratio varies from 2.4:1
to below 1:1 depending on the report [1-3]. AKC is the most
debilitating of the allergic conjunctival diseases, owing to its
chronicity and ability to cause loss of vision due to frequent
corneal  complications  [1,4,5].  Ocular  symptoms  include
intense  itching,  photophobia,  burning,  and  foreign  body
sensation. The clinical signs are observed as corneal staining,
conjunctival injection, edema, and papillae on the upper tarsal
conjunctiva.  In  the  most  severe  cases,  ulceration  and
neovascularization of the cornea, subepithelial fibrosis of the
conjunctiva, fornix shortening, and symblepharon are present.
Eosinophils,  mast  cells,  neutrophils  and  lymphocytes,
specially activated T-cells, are seen in conjunctival cytology
as an inflammatory response of the atopic disease [6-8]. We
previously reported the presence of neutrophils and dendritic
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cells  in  conjunctival  epithelium  and  papillary  formations
visualized by in vivo confocal scanning microscopy of the
upper palpebral conjunctiva [9]. Owing to the complexity,
chronicity and multifactorial nature of the AKC disease, no
evidence exists showing a significant therapeutic effect on the
disease  course.  The  goals  of  treatment  are  to  achieve
symptomatic  control,  reduce  the  frequency  of  corneal
complications and their morbidity, and to minimize the side
effects of treatment.
Treatment  of  AKC  based  on  eye-drops  containing
antihistamines or sodium chromoglycate and its derivates are
often insufficient [10,11]. The addition of steroids is usually
mandatory. Although these agents often achieve symptomatic
and inflammatory control in a short time of treatment, they
present disadvantages well recognized as their side effects,
including glaucoma, cataract, herpes simplex virus keratitis,
and atrophy of the derma of the eyelids [12] that limit its use
to short courses, resulting in inadequate long-term treatment
responses.  As  an  alternative  to  steroids,  several
immunosuppressive  medications  have  been  considered.
Cyclosporine  eye  drops,  tacrolimus  ointment  and  most
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932recently tacrolimus eye drops have been released for use in
ocular allergy [13-15].
Tacrolimus (FK-506) is a strong immunosuppressant that
inhibits  the  proliferative  response  of  lymphocytes  to
alloantigen  stimulation  and  a  variety  of  T  cell  associated
immune reactions. It has been isolated from the fermentation
broth of Streptomyces tsukubaenis as colorless prism and the
molecular formula was determined as C44H69NO12.H2O.
Tacrolimus suppresses the immune responses by inhibiting
the inflammatory cytokine release (e.g., interleukin-2, IL-3,
IL-4, IL-5, IL-8, interferon-gamma, tumor necrosis factor-α)
and  also  down-regulates  the  high-affinity  IgE  receptor  I
(FcRI)  expression  on  Langerhans  cells  [16-20]  without
adversely affecting connective tissue [21]. It has been shown
to be a potent immunosuppressive agent in vivo and in vitro.
Tacrolimus  shares  several  immunosuppressive  properties
with cyclosporine A, although it is known to be 10 to 100 times
more potent in this regard [22,23]. Its safety and efficacy in
the treatment of atopic dermatitis have been demonstrated in
short- and long-term studies with adult and pediatric patients
[17-19,24,25].  Previous  studies  on  the  use  of  tacrolimus
ointment in atopic eyelid disease have also shown good levels
of response and improvement in conjunctivitis symptoms,
with no significant adverse events [26,27].
Eosinophil cationic protein (ECP) is one of several highly
basic  proteins  present  in  the  secretory  granule  of  the
eosinophil that is released upon its activation. ECP has already
been found to play an important role in the pathogenesis of
allergic conjunctivitis and tear ECP levels in allergic patients
are known to be related to the severity of clinical findings
[28-31].
The purpose of this study was to examine the clinical
efficacy  and  anti-inflammatory  effects  of  tacrolimus  eye
drops, evaluating the changes of clinical ocular findings and
measuring tear ECP levels of AKC patients before and after
treatment.
METHODS
Subjects: This study was conducted at the Ocular Allergy
Subspecialty Clinic of the Department of Ophthalmology,
Mita Hospital, International University of Health and Welfare
(Tokyo,  Japan).  The  study  protocol  was  approved  by  the
Ethical Committee of Mita Hospital, International University
of Health and Welfare review board. This study adhered to the
tenets  of  the  Declaration  of  Helsinki.  The  clinical  trial
registration number is UMIN000001262.
Nine eyes of 9 AKC patients (8 males, 1 female) aged
between 6 and 44 years (mean age: 16.9 years) were recruited
sequentially from June 2008 to February 2010 in a prospective
study. All patients were known to have had a long-standing
AKC that was previously treated with steroids eye-drops.
Patients were selected based on the criteria established by
Hogan [32]: chronic conjunctivitis and progressive keratitis
in association with atopic keratoconjunctivitis, and presence
of a hereditary allergic tendency. All patients had moderate to
severe  AKC  disease  with  presence  of  cobblestone-like
papillae,  severe  injection  and  edema  of  the  upper  tarsal
conjunctiva and moderate to severe corneal staining scores or
ulcers as markers of severe activity and inflammation. Some
of them presented elevation of the intraocular pressure due to
previous steroid treatment or were refractory to the standard
steroid regime. None of the patients had a history of Stevens-
Johnson  syndrome,  chemical,  thermal,  radiation  injury,
bacterial, viral or toxic conjunctivitis, or underwent any ocular
surgery that would create an ocular surface problem. Subjects
in this study did not have a history of contact lens use. Any
patient  was  being  treated  with  systemic  cytotoxic
immunosuppressants, steroids and prostaglandin inhibitors.
Procedures and visits: Patients received 0.1% tacrolimus eye
drops (Senju Pharma Inc., Osaka, Japan) 2 times a day for 1
month. As the ethic board committee did not allow a washout
period in subjects with an active disease to study the naïve
ocular  surface  status,  all  the  anti-allergic  and  anti-
inflammatory medications that the subjects were using on the
recruitment day were discontinued and the new medication
was started on the next day (day one of the treatment). The
administration of other topically drugs except lubricant was
not allowed during the study period.
Patients attended several follow-up visits, considering
that some of them had corneal erosion or ulcer and underwent
tear collection, slit-lamp examination including fluorescein
staining,  conjunctival  injection,  and  edema  and  papillae
formation grading before and after 1 month of treatment.
Venus  peripheral  blood  was  collected  and  enzyme-linked
immunosorbent assay (ELISA) test was used to detect the
specific IgE antibodies to 26 allergens was performed using
the  MAST  26  Allergen  Kit  in  all  subjects  (SRL,  Tokyo,
Japan).
TABLE 1. COMPARISON OF CLINICAL SIGNS AND OCULAR SURFACE VITAL STAINING SCORES BEFORE AND AFTER TREATMENT WITH TACROLIMUS
Clinical signs and ocular surface vital staining scores Before treatment After 1 month of
treatment
p value
Conjunctival injection score(0–3 points) 2.89±0.33 1.00±0.53 0.004
Conjunctival edema score (0–3 points) 2.78±0.67 1.00±0.92 0.016
Papillary proliferation score (0–3 points) 3.00±0.01 2.62±1.06 0.500
Fluorescein staining (0–9 points) 5.50±4.14 0.28±0.75 0.016
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933Slit lamp examination: A conventional slit-lamp microscopic
examination was performed. Two microliters of preservative-
free 1% fluorescein preservative-free solution was instilled in
the conjunctival sac with a micropipette. The subjects were
then instructed to blink several times for a few seconds to
ensure adequate covering of the dye onto the ocular surface.
Fluorescein staining of the cornea was noted and scored. The
cornea was divided into 3 equal upper, middle, and lower
zones. Each zone had a staining score ranging between 0 and
3  points,  with  the  minimum  and  maximum  total  staining
scores ranging between 0 to 9 points. Likewise, the presence
of scarce staining in zone 1 was scored as 1 point, whereas
punctate staining covering the entire zone was scored as 3
points. A score >3 points was regarded as abnormal [33,34].
Three major upper tarsal conjunctival findings such as
conjunctival injection, edema, and papillary formation were
assessed, and a clinical severity score [35] was assigned for
each finding. The severity of the signs was graded as follows:
score 0-absence of signs; score 1-mild; score 2-moderate and
3-severe conjunctival injection, edema or papillary formation.
Tear  analysis:  Tear  collection  was  performed  before  the
treatment  and  during  the  first  month  of  treatment  with
tacrolimus. With the use of a capillary micropipette, tears were
gently collected from the external canthus, taking precaution
to avoid reflex tearing. Tear samples were collected and then
patients were asked to wait at least 30 min before the vital
staining examination. Following collection, tears were placed
in Eppendorff tubes and centrifuged at 13,600× g for 5 min at
4  °C.  The  supernatants  were  then  stored  at  −80  °C  until
assayed.
A commercially available ECP ELISA kit (MBL, Tokyo,
Japan)  was  used  to  determine  the  ECP  concentration,
according to the product protocol. We also investigated the
correlation between tear ECP levels and cornea fluorescein
staining  scores,  conjunctival  injection,  edema,  as  well  as
conjunctival papillary proliferation.
Statistical analysis: The Wilcoxon signed rank test was used
to compare the baseline values with the post-treatment values.
Spearman  correlation  test  was  used  to  explore  various
associations: ECP concentration and fluorescein scores, ECP
concentration and conjunctival injection, ECP concentration
and  papillary  proliferation  and  ECP  concentration  and
conjunctival  edema.  Data  were  processed  using  Instat,
GraphPad software version Instat 3.0 (San Diego, CA).
RESULTS
Patient characteristics: Overall, the disease activity in the
study group was moderate to severe. All 9 patients completed
the  study.  Compliance  and  documentation  were  generally
satisfactory.  There  were  no  complains  of  burning  or  heat
sensation, the most common adverse effects of the tacrolimus
ointments. None of the patients presented episode of herpetic
keratitis during the treatment with tacrolimus. No significant
changes in the intraocular pressure, cornea, lens, refraction or
anterior chamber occurred in any patients during the treatment
with topical tacrolimus.
Effect  on  clinical  signs  and  ocular  surface  vital  staining
scores: The mean fluorescein staining scores were 5.50±4.14
points and 0.28±0.75 points in AKC patients before and after
treatment with tacrolimus eye-drops, respectively. We could
Figure  1.  Representative  anterior
segment  photographs  from  an  AKC
patient before and after treatment with
tacrolimus  ophthalmic  solution.
Anterior  segment  photograph  (right)
shows  an  extensive  corneal  damage
visualized by the fluorescein staining.
Note  that  the  superficial  punctate
keratopathy is present in almost all the
surface of the cornea and is associated
to  the  increased  papillary  formation.
The  photographs  on  the  left  side
represent  the  cornea  and  papillary
formation from the same patient after 1
month  of  treatment  with  0.1%
tacrolimus  ophthalmic  solution.  Note
the improvement of the corneal damage
as  well  as  the  decrease  of  papillary
formation  and  conjunctival
inflammatory status.
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934observe a statistically significant difference between the pre-
and post-treatment values (p<0.05) as shown in Table 1.
The pre-treatment mean conjunctival injection score was
2.89±0.33.  After  drug  therapy,  the  mean  conjunctival
injection  score  was  significantly  (p<0.05)  decreased  to
1.00±0.53. The pre-treatment mean conjunctival edema score
was 2.78±0.67, and after 1 month of treatment, 1.00±0.92. The
clinical conjunctival edema score was significantly decreased
(p<0.05) after therapy, as shown in Table 1. A representative
case of improvement in clinical findings after 1 month of
treatment with tacrolimus is shown in Figure 1.
The mean papillary formation score was not significantly
different after treatment (2.62±1.06) when compared with the
mean  value  before  treatment  with  tacrolimus  (3.00±0.01;
p=0.500, Table 1).
Tear ECP concentrations: The mean pre and post-treatment
tear ECP concentrations were 2,680.22±2,342.7 ng/ml and
195.71±164.46 ng/ml, respectively. A significantly difference
in  relation  to  the  pre-  and  post-treatment  tear  ECP
concentrations was observed (p<0.05; Figure 2).
We observed a significant positive correlation between
tear  ECP  concentrations  with  corneal  fluorescein  (r=0.70,
p=0.0039),  conjunctival  injection  (r=0.65,  p=0.0044)  and
edema scores (r=0.60, p=0.0114), as shown in Figure 3.
DISCUSSION
The results of our pilot study demonstrate that tacrolimus was
effective in reducing signs of AKC in 9 subjects over a month
of period.
Previous  studies  has  shown  that  tacrolimus  0.3%
eyedrops  can  inhibit  the  infiltration  of  eosinophils  and
lymphocytes  significantly  in  experimental  animal  models
[36].  In  another  study,  0.1%–1%  tacrolimus  eyedrops
inhibited the late and delayed-type inflammatory response of
experimental animal allergic conjunctivitis with an efficacy
similar  to  that  of  betamethasone  0.1%  eyedrops  [37].
Tacrolimus is a very hydrophobic macrolide lactone with a
molecular weight of approximately 800 daltons. Because of
its characteristics and relatively large molecular size, it should
penetrate the corneal epithelium with some difficulty and
accumulate  in  the  cornea  stroma.  This  may  result  in  low
intraocular  drug  levels  [38].  However,  when  the  corneal
epithelial barrier is broken it certainly penetrates easier than
over an intact ocular surface which may confer successful
treatment  in  the  severe  cases.  Because  of  these  drug
characteristics,  patients  with  conjunctival  inflammatory
conditions  should  theoretically  respond  better  to  topical
tacrolimus than patients with inflammatory conditions such
as penetrating keratoplasty rejection and uveitis.
Figure 2. Comparison of tear ECP levels
before  and  after  treatment  with  0.1%
tacrolimus  eye-drops.  Note  the
significant decrease in the ECP values
in patients treated with tacrolimus eye-
drops for 1 month.
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935The papillary formation score did not show significant
difference. We thought one month period of treatment was not
sufficient to observe significant changes in the improvement
of papilla formation. Moreover, some cases in 9 patients were
longstanding  cases  of  AKC  and  once  fibrosis  in  papilla
formation  was  established  the  medication  affected  less
significant.
In our study, we observed significantly decrease in the
ECP  values  after  1  month  of  treatment  with  tacrolimus.
Furthermore, strong positive linear correlations between ECP
values and clinical signs were observed. By measuring ECP
levels in tears of patients with allergic conjunctivitis, one can
estimate the degree of inflammation and may also assess the
correlation of the mediators to the severity of the clinical
findings. The measurement of ECP levels seems to be one
potent marker to do the follow-up of allergic conjunctivitis
and evaluate the responsiveness to a specific treatment.
The  main  findings  of  this  study  suggest  that  0.1%
tacrolimus ophthalmic solution offers an efficient option for
the treatment of severe AKC, although this pilot group is
based in a small number of subjects and the course of the
treatment is maybe considered short. The measurement of
ECP demonstrated to be an important marker in the diagnosis
and monitoring of the atopic disease, and also may prove to
be useful tool for the evaluation of new therapies for the AKC
disease.
It remains the further goal of future studies to determine
how are the changes of inflammatory cytokines and markers
of inflammation in response of treatment with tacrolimus.
Such  investigations  will  give  insight  into  the  underlying
mechanisms of tacrolimus and atopic keratoconjunctivitis.
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